Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor achieves milestone in collaboration with CSL
The filing of an investigational new drug application with the FDA for a monoclonal antibody that was optimized using Xencor’s XmAb antibody technology prompted the milestone payment. Xencor
The filing of an investigational new drug application with the FDA for a monoclonal antibody that was optimized using Xencor’s XmAb antibody technology prompted the milestone payment. Xencor
Daclatasvir is an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor. In the Phase II open-label clinical trial (AI447-017), patients were divided into two
ALD518 is a monoclonal antibody to the pro-inflammatory cytokine IL-6, which is under Phase 2 development by Bristol-Myers Squibb for autoimmune diseases, and by Alder for cancer-related conditions.
Admet Predictor 6.0 now integrated with MedChem Designer offers graphical user interface improvements, expanded multidimensional graphics output and enhanced capabilities for exporting results. SLP Admet cheminformatics team leader
The company began the shipment of generic Fortamet (metformin hydrochloride extended-release tablets). Fortamet is indicated as an adjunct to diet and exercise to lower blood glucose for patients
The dexlansoprazole capsules are the generic version of Takeda’s Dexilant. As per the agreement, Par made a payment to Handa for the ANDA, giving it the exclusive rights
Carisbamate has previously been shown to have efficacy in trials for adult forms of epilepsy, such as partial onset seizures. IS is a form of epilepsy associated with
The new site will facilitate operations supporting plasma fractionation, purification, fill-finish and a testing lab. Commercial production is scheduled to begin in 2018, with the new plasma fractionation
GSK offered $13 per share, which is 81% premium to HGS closing price on 18 April 2012, of $7.17 per share. HGS has partnered Glaxo in the development
As a part of the agreement, MJFF will sponsor the study, owns and shares all the data and results generated by the trial. Further development plans will depend